In vitro activities of 8 antifungal drugs against 126 clinical and environmental Exophiala isolates
© 2021 Wiley-VCH GmbH..
BACKGROUND: Exophiala is the main genus of black fungi comprising numerous opportunistic species. Data on antifungal susceptibility of Exophiala isolates are limited, while infections are potentially fatal.
MATERIALS AND METHODS: In vitro activities of eight antifungal drugs (AMB, five azoles, two echinocandins) against 126 clinical (n = 76) and environmental (n = 47) isolates from around the world were investigated. E. oligosperma (n = 58), E. spinifera (n = 33), E. jeanselmei (n = 14) and E. xenobiotica (n = 21) were included in our dataset.
RESULTS: The resulting MIC90 s of all strains were as follows, in increasing order: posaconazole 0.063 μg/ml, itraconazole 0.125 μg/ml, voriconazole and amphotericin B 1 μg/ml, isavuconazole 2 μg/ml, micafungin and caspofungin 4 μg/ml, and fluconazole 64 μg/ml. Posaconazole, itraconazole and micafungin were the drugs with the best overall activity against Exophiala species. Fluconazole could not be considered as a treatment choice. No significant difference could be found among antifungal drug activities between these four species, neither in clinical nor in environmental isolates.
CONCLUSION: Antifungal susceptibility data for Exophiala spp. are crucial to improve the management of this occasionally fatal infection and the outcome of its treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:64 |
|---|---|
| Enthalten in: |
Mycoses - 64(2021), 11 vom: 30. Nov., Seite 1328-1333 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Najafzadeh, Mohammad Javad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antifungal Agents |
|---|
| Anmerkungen: |
Date Completed 04.11.2021 Date Revised 04.11.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/myc.13364 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329548085 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329548085 | ||
| 003 | DE-627 | ||
| 005 | 20231225205342.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/myc.13364 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1098.xml |
| 035 | |a (DE-627)NLM329548085 | ||
| 035 | |a (NLM)34411353 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Najafzadeh, Mohammad Javad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In vitro activities of 8 antifungal drugs against 126 clinical and environmental Exophiala isolates |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.11.2021 | ||
| 500 | |a Date Revised 04.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 Wiley-VCH GmbH. | ||
| 520 | |a BACKGROUND: Exophiala is the main genus of black fungi comprising numerous opportunistic species. Data on antifungal susceptibility of Exophiala isolates are limited, while infections are potentially fatal | ||
| 520 | |a MATERIALS AND METHODS: In vitro activities of eight antifungal drugs (AMB, five azoles, two echinocandins) against 126 clinical (n = 76) and environmental (n = 47) isolates from around the world were investigated. E. oligosperma (n = 58), E. spinifera (n = 33), E. jeanselmei (n = 14) and E. xenobiotica (n = 21) were included in our dataset | ||
| 520 | |a RESULTS: The resulting MIC90 s of all strains were as follows, in increasing order: posaconazole 0.063 μg/ml, itraconazole 0.125 μg/ml, voriconazole and amphotericin B 1 μg/ml, isavuconazole 2 μg/ml, micafungin and caspofungin 4 μg/ml, and fluconazole 64 μg/ml. Posaconazole, itraconazole and micafungin were the drugs with the best overall activity against Exophiala species. Fluconazole could not be considered as a treatment choice. No significant difference could be found among antifungal drug activities between these four species, neither in clinical nor in environmental isolates | ||
| 520 | |a CONCLUSION: Antifungal susceptibility data for Exophiala spp. are crucial to improve the management of this occasionally fatal infection and the outcome of its treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Exophiala spp. | |
| 650 | 4 | |a antifungal susceptibility | |
| 650 | 4 | |a black yeast | |
| 650 | 4 | |a posaconazole | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 700 | 1 | |a Dolatabadi, Somayeh |e verfasserin |4 aut | |
| 700 | 1 | |a Vicente, Vania Aparecida |e verfasserin |4 aut | |
| 700 | 1 | |a de Hoog, Gerrit Sybren |e verfasserin |4 aut | |
| 700 | 1 | |a Meis, Jacques F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mycoses |d 1990 |g 64(2021), 11 vom: 30. Nov., Seite 1328-1333 |w (DE-627)NLM01265194X |x 1439-0507 |7 nnns |
| 773 | 1 | 8 | |g volume:64 |g year:2021 |g number:11 |g day:30 |g month:11 |g pages:1328-1333 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/myc.13364 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 64 |j 2021 |e 11 |b 30 |c 11 |h 1328-1333 | ||